UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Medpace Holdings, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 32-0434904 (I.R.S. Employer Identificat ...

Medpace Holdings, Inc. (NASDAQ:MEDP) Q1 2022 Earnings Conference Call April 26, 2022 9:00 AM ET Company Participants Lauren Morris ??? Director-Investor Relations August Troendle ??? Chief Executive Officer Jesse Geiger ??? President Kevin Brady ??? Chief Financial Officer Conference Call Participants Dave Windley ??? Jefferies Eric Coldwell ??? Baird Christine Rains ??? William Blair Paul Knight ??? KeyBanc Operator Good day, ladies and gentlemen, and welcome to the Medpace First Quarter 2022 Earnings Conf ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0434904 (State or other jurisdicti ...

Medpace Holdings, Inc. (NASDAQ:MEDP) Q4 2021 Earnings Conference Call February 15, 2022 9:00 AM ET Company Participants Lauren Morris - Associate Director, Investors Relations August Troendle - Chairman & CEO Jesse Geiger - President Kevin Brady - CFO & Treasurer Conference Call Participants John Kreger - William Blair & Company Donald Hooker - KeyBanc Capital Markets Operator Good day, ladies and gentlemen, and welcome to the Medpace Fourth Quarter and Full Year 2021 Earnings Conference Call. [Operator Ins ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | FORWARD LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial results, the ant ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 5375 Medpace Way, Cincinnati, OH 45227 (Address of principal executive offices) (Zip Code) (513) 579-9911 (Registra ...

Medpace Holdings, Inc. (NASDAQ:MEDP) Q3 2021 Earnings Conference Call October 26, 2021 9:00 AM ET Company Participants Lauren Morris - Director of Investor Relations August Troendle - CEO Jesse Geiger - President Kevin Brady - CFO Conference Call Participants John Kreger - William Blair Donald Hooker - KeyBanc Dave Windley - Jefferies Operator Good day, ladies and gentlemen, and welcome to the Medpace Third Quarter 2021 Earnings Conference Call [Operator Instructions]. As a reminder, this call may be record ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0434904 (State or other jurisd ...

Medpace Holdings, Inc. (NASDAQ:MEDP) Q2 2021 Earnings Conference Call July 27, 2021 9:00 AM ET Company Participants Lauren Morris - Associate Director of IR August Troendle - President and CEO Jesse Geiger - CFO and COO, Laboratory Operations Kevin Brady - Executive Director of Finance Conference Call Participants Justin Lin - William Blair Dave Windley - Jefferies Operator Good day, ladies and gentlemen, and welcome to the Medpace Second Quarter 2021 Earnings Conference Call. At this time, all participants ...

[PART I — FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20%E2%80%94%20FINANCIAL%20INFORMATION) [Financial Statements (unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements for Q1 2021, including balance sheets, statements of operations, and cash flows, with accompanying notes Condensed Consolidated Statements of Operations (Q1 2021 vs Q1 2020) | (Amounts in thousands, except per share amounts) | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | | :--- | :--- | :--- | | **Revenue, net** | **$259,965** | **$230,879** | | Income from operations | $47,599 | $35,504 | | **Net income** | **$43,306** | **$28,954** | | Diluted EPS | $1.14 | $0.76 | Condensed Consolidated Balance Sheets Highlights | (Amounts in thousands) | March 31, 2021 | December 31, 2020 | | :--- | :--- | :--- | | Cash and cash equivalents | $332,877 | $277,766 | | Total current assets | $533,380 | $473,651 | | **Total assets** | **$1,451,360** | **$1,390,677** | | Total current liabilities | $447,306 | $440,110 | | **Total liabilities** | **$592,433** | **$584,898** | | **Total shareholders' equity** | **$858,927** | **$805,779** | Condensed Consolidated Statements of Cash Flows (Q1 2021 vs Q1 2020) | (Amounts in thousands) | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | | :--- | :--- | :--- | | Net cash provided by operating activities | $57,319 | $49,148 | | Net cash used in investing activities | ($9,651) | ($5,522) | | Net cash provided by (used in) financing activities | $9,102 | ($40,445) | | **Increase in cash, cash equivalents, and restricted cash** | **$55,111** | **$2,079** | - As of March 31, 2021, **$102.6 million** remained authorized for share repurchases, with no repurchases in Q1 2021, contrasting with **$43.2 million** for **661,637 shares** in Q1 2020[21](index=21&type=chunk) - The company had approximately **$1.8 billion** in remaining performance obligations for active projects as of March 31, 2021[35](index=35&type=chunk) Revenue by Therapeutic Area (Q1 2021 vs Q1 2020) | Therapeutic Area | Q1 2021 Revenue (in thousands) | Q1 2020 Revenue (in thousands) | | :--- | :--- | :--- | | Oncology | $79,138 | $69,212 | | Other | $68,938 | $50,569 | | Metabolic | $32,495 | $36,075 | | AVAI | $30,820 | $25,147 | | Central Nervous System | $24,812 | $23,977 | | Cardiology | $23,762 | $25,899 | | **Total revenue** | **$259,965** | **$230,879** | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=16&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2021 financial results, highlighting a **12.6% increase in net revenue** to **$260.0 million** and a significant rise in net income, alongside key performance metrics and liquidity Key Performance Metrics (Q1 2021 vs Q1 2020) | Metric | Q1 2021 | Q1 2020 | | :--- | :--- | :--- | | Net new business awards | $356.2 million | $246.9 million | | Backlog (as of March 31) | $1,631.8 million | $1,294.2 million | - The company expects to convert approximately **$850 million to $870 million** of its backlog to net revenue over the next twelve months[76](index=76&type=chunk) - The COVID-19 pandemic continues to cause temporary disruptions, primarily impacting physical access to sites, patient enrollment, and trial start-up activities[82](index=82&type=chunk) - Net revenue increased by **$29.1 million (12.6%)** in Q1 2021 compared to Q1 2020, driven by growth in Oncology, AVAI, and other therapeutic areas[86](index=86&type=chunk) - The effective tax rate decreased to **10.7%** in Q1 2021 from **20.6%** in Q1 2020, primarily due to increased tax benefits from FDII and share-based compensation[92](index=92&type=chunk) - The company maintained a strong liquidity position with **$332.9 million** in cash and cash equivalents and **$49.8 million** available under its credit facility as of March 31, 2021[93](index=93&type=chunk)[94](index=94&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=23&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) No material changes have occurred in the company's quantitative and qualitative market risk disclosures since the 2020 Annual Report on Form 10-K - No material changes have occurred in the company's market risk disclosures compared to the 2020 Form 10-K[109](index=109&type=chunk) [Controls and Procedures](index=23&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2021, with no material changes to internal control over financial reporting during the quarter - Management concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of March 31, 2021[111](index=111&type=chunk) - No changes in internal control over financial reporting occurred during Q1 2021 that materially affected, or are reasonably likely to materially affect, these controls[113](index=113&type=chunk) [PART II — OTHER INFORMATION](index=24&type=section&id=PART%20II%20%E2%80%94%20OTHER%20INFORMATION) [Legal Proceedings](index=24&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in incidental legal proceedings not expected to materially affect its financial statements - The company is involved in legal proceedings incidental to its business, which are not expected to have a material adverse effect on its financial statements[114](index=114&type=chunk) [Risk Factors](index=24&type=section&id=Item%201A.%20Risk%20Factors) No significant changes have occurred to the risk factors previously disclosed in the 2020 Annual Report on Form 10-K - No significant changes have occurred to the risk factors disclosed in the 2020 Annual Report on Form 10-K[115](index=115&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=25&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details the issuance of common stock from employee stock option exercises in Q1 2021, exempt from registration under Rule 701 - During Q1 2021, employees exercised **223,758 stock options** under the 2014 Equity Incentive Plan for approximately **$3.4 million**[117](index=117&type=chunk) - These issuances were exempt from registration under Rule 701 of the Securities Act of 1933 as part of employee benefit plans[117](index=117&type=chunk) [Defaults Upon Senior Securities](index=25&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities during the period - None[119](index=119&type=chunk) [Mine Safety Disclosures](index=25&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[120](index=120&type=chunk) [Other Information](index=26&type=section&id=Item%205.%20Other%20Information) The company reports no other information to be disclosed for the period - None[121](index=121&type=chunk) [Exhibits](index=26&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed as part of the quarterly report, including a loan agreement amendment, CEO/CFO certifications, and Inline XBRL documents - Exhibits filed with the report include an amendment to the Loan Agreement, CEO and CFO certifications (Rule 13a-14(a) and Section 1350), and Inline XBRL data files[122](index=122&type=chunk)[124](index=124&type=chunk)